ResearcherChinese PLA General HospitalActive in the last 2 years

Guanghai Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8986-6027; OpenAlex author ID A5034620851. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metast… Last author DOI 10.1038/s41392-025-02441-2 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ru Jia · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Quanli Han · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Mengjiao Fan · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Guochao Deng · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.